residual limb pain

Pain clinical trials span acute procedural pain, chronic musculoskeletal pain, neuropathic pain, and cancer-related pain — each requiring distinct trial designs and patient-reported outcome instruments. The regulatory demand for non-opioid alternatives has intensified the search for novel analgesic mechanisms, particularly ion channel targets and neurostimulation approaches.

Active trials evaluate Nav1.7/1.8 blockers, CGRP antagonists for new indications, spinal cord stimulation refinements, virtual reality-based pain management, and patient-specific ketamine infusion protocols. Pain trials increasingly use ecological momentary assessment (EMA) diary approaches over traditional recall-based pain rating scales.